Spot Trading’s Cardiff Oncology CRDF Stock Holding History

Spot Trading’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-165	Closed	-$54K	–	3132
2016 Q2	$54K	Buy	+165	New	+$56.8K	﹤0.01%	2735

Other funds holding CRDF

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Spot Trading's CRDF Position: Q3 2016 in Review

Spot Trading sold out of Cardiff Oncology (CRDF) in Q3 2016, closing a stake of 95 shares — an estimated $31K sold.

Spot Trading first reported a position in CRDF in Q2 2016 and held it in 1 quarter. The position peaked at $31K in Q2 2016. 66 funds tracked by Wall St. Rank hold CRDF as of Q3 2016.

Spot Trading reported no remaining Cardiff Oncology position as of Q3 2016 after selling out during the quarter.
Spot Trading sold 95 Cardiff Oncology shares in Q3 2016, an estimated $31K.
Spot Trading first reported a position in Cardiff Oncology in Q2 2016 and held it in 1 quarter.
Spot Trading's Cardiff Oncology position peaked at $31K in Q2 2016.
66 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.